Compare Stocks: VKTX, NVO, LLY, and GS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GS The Goldman Sachs Group	$1,006.28 +0.4%	$1,045.40	$722.30 ▼ $1,153.99	$293.01B	1.29	2.21 million shs	652,370 shs
LLY Eli Lilly and Company	$1,167.94 +0.7%	$1,191.34	$712.05 ▼ $1,292.65	$1.10T	0.5	3.07 million shs	642,463 shs
NVO Novo Nordisk A/S	$46.51 +3.1%	$47.98	$35.12 ▼ $64.16	$207.70B	0.75	17.43 million shs	4.71 million shs
VKTX Viking Therapeutics	$33.24 -1.3%	$35.63	$22.96 ▼ $43.15	$3.88B	0.69	2.51 million shs	640,688 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GS The Goldman Sachs Group	-2.71%	-5.76%	-1.93%	-4.34%	+34.07%
LLY Eli Lilly and Company	-0.09%	-5.88%	+0.89%	+7.23%	+58.32%
NVO Novo Nordisk A/S	-0.51%	-7.27%	-4.43%	+7.26%	-20.17%
VKTX Viking Therapeutics	+2.72%	-1.46%	+6.08%	+14.80%	+24.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GS The Goldman Sachs Group	$1,006.28 +0.4%	$1,045.40	$722.30 ▼ $1,153.99	$293.01B	1.29	2.21 million shs	652,370 shs
LLY Eli Lilly and Company	$1,167.94 +0.7%	$1,191.34	$712.05 ▼ $1,292.65	$1.10T	0.5	3.07 million shs	642,463 shs
NVO Novo Nordisk A/S	$46.51 +3.1%	$47.98	$35.12 ▼ $64.16	$207.70B	0.75	17.43 million shs	4.71 million shs
VKTX Viking Therapeutics	$33.24 -1.3%	$35.63	$22.96 ▼ $43.15	$3.88B	0.69	2.51 million shs	640,688 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GS The Goldman Sachs Group	-2.71%	-5.76%	-1.93%	-4.34%	+34.07%
LLY Eli Lilly and Company	-0.09%	-5.88%	+0.89%	+7.23%	+58.32%
NVO Novo Nordisk A/S	-0.51%	-7.27%	-4.43%	+7.26%	-20.17%
VKTX Viking Therapeutics	+2.72%	-1.46%	+6.08%	+14.80%	+24.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GS The Goldman Sachs Group	2.54	Moderate Buy	$1,062.86	5.62% Upside
LLY Eli Lilly and Company	2.83	Moderate Buy	$1,292.18	10.64% Upside
NVO Novo Nordisk A/S	2.16	Hold	$64.94	39.61% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$96.63	190.70% Upside

Current Analyst Ratings Breakdown

Latest VKTX, NVO, LLY, and GS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Buy
8/27/2026	NVO Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell
8/26/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/18/2026	VKTX Viking Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$47.00
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/11/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	NVO Novo Nordisk A/S	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	VKTX Viking Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$75.00 ➝ $65.00
8/7/2026	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1,376.00
8/7/2026	LLY Eli Lilly and Company	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,370.00 ➝ $1,376.00

(Data available from 9/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GS The Goldman Sachs Group	$66.20B	4.43	$63.29 per share	15.90	$376.80 per share	2.67
LLY Eli Lilly and Company	$65.18B	16.87	$25.38 per share	46.01	$35.99 per share	32.45
NVO Novo Nordisk A/S	$329.43B	0.63	$4.81 per share	9.67	$6.58 per share	7.07
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$3.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GS The Goldman Sachs Group	$17.18B	$64.79	15.53	13.92	1.04	15.53%	19.16%	1.07%	10/13/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	39.25	25.46	1.36	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	11.37	13.60	4.05	35.36%	61.20%	21.49%	11/4/2026 (Estimated)
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest VKTX, NVO, LLY, and GS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A
7/14/2026	Q2 2026	GS The Goldman Sachs Group	$14.47	$20.98	+$6.51	$20.98	$16.22 billion	$20.34 billion
6/30/2026	Q2 2026	NVO Novo Nordisk A/S	N/A	$0.9440	N/A	$0.72	N/A	$11.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GS The Goldman Sachs Group	$20.00	1.99%	+22.87%	30.87%	13 Years
LLY Eli Lilly and Company	$6.92	0.59%	+15.18%	23.22%	11 Years
NVO Novo Nordisk A/S	$0.81	1.74%	+21.74%	19.80%	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest VKTX, NVO, LLY, and GS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/13/2026	GS The Goldman Sachs Group	quarterly	$5.00	2%	9/1/2026	9/1/2026	9/29/2026
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.59%	8/14/2026	8/14/2026	9/10/2026
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.58%	8/17/2026	8/17/2026	8/25/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GS The Goldman Sachs Group	3.17	0.63	0.63
LLY Eli Lilly and Company	1.41	1.35	1.00
NVO Novo Nordisk A/S	0.59	0.79	0.56
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GS The Goldman Sachs Group	71.21%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
GS The Goldman Sachs Group	0.55%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GS The Goldman Sachs Group	47,400	291.17 million	289.57 million	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
VKTX Viking Therapeutics	20	116.65 million	110.47 million	Optionable

VKTX, NVO, LLY, and GS Headlines

Recent News About These Companies

Quantitative Investment Management LLC Invests $1.61 Million in Viking Therapeutics, Inc. $VKTX

September 1 at 6:07 AM | marketbeat.com

Bank of New York Mellon Corp Takes Position in Viking Therapeutics, Inc. $VKTX

September 1 at 3:35 AM | marketbeat.com

VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3

August 31 at 10:28 PM | stocktwits.comS

Viking Therapeutics Is Down 66% — Here’s What Could Bring It Back

August 31 at 12:25 PM | nai500.comN

Viking Therapeutics Is Down 66% — Here’s What Could Bring It Back

August 31 at 12:25 PM | nai500.comN

Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Rating of "Moderate Buy" from Analysts

August 31 at 2:28 AM | americanbankingnews.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 31 at 2:28 AM | marketbeat.com

Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.

August 30 at 3:45 PM | fool.com

Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?

August 30 at 3:12 AM | finance.yahoo.com

Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?

August 28, 2026 | zacks.com

Man Group plc Acquires Shares of 312,171 Viking Therapeutics, Inc. $VKTX

August 28, 2026 | marketbeat.com

Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?

August 27, 2026 | fool.com

6,189,649 Shares in Viking Therapeutics, Inc. $VKTX Purchased by BlackRock Inc.

August 27, 2026 | marketbeat.com

Artia Global Partners LP Buys New Position in Viking Therapeutics, Inc. $VKTX

August 27, 2026 | marketbeat.com

Kintayl Capital LP Buys New Shares in Viking Therapeutics, Inc. $VKTX

August 26, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $20.70 Million in Viking Therapeutics, Inc. $VKTX

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Takes $22.39 Million Position in Viking Therapeutics, Inc. $VKTX

August 26, 2026 | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 32,564 Viking Therapeutics, Inc. $VKTX

August 22, 2026 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Upgraded to Hold at Zacks Research

August 20, 2026 | marketbeat.com

How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?

August 19, 2026 | finance.yahoo.com

Timothy G. Youngquist 2020 Irrevocable Trust Has $10.61 Million Position in Viking Therapeutics, Inc. $VKTX

August 19, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VKTX, NVO, LLY, and GS Company Descriptions

The Goldman Sachs Group NYSE:GS

$1,006.28 +3.72 (+0.37%)

As of 11:58 AM Eastern

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Eli Lilly and Company NYSE:LLY

$1,167.94 +7.94 (+0.68%)

As of 11:58 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$46.51 +1.39 (+3.09%)

As of 11:58 AM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Viking Therapeutics NASDAQ:VKTX

$33.24 -0.43 (-1.28%)

As of 11:58 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VKTX, NVO, LLY, and GS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VKTX, NVO, LLY, and GS Earnings

Compare Dividends

Latest VKTX, NVO, LLY, and GS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VKTX, NVO, LLY, and GS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VKTX, NVO, LLY, and GS Company Descriptions

The Goldman Sachs Group NYSE:GS

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools